News and Trends 31 Jan 2023 Active Biotech trial confirms eye treatment safety …for treatment of severe eye disorders, including uveitis and eye disorders with abnormal vascularization. Current portfolio of Active Biotech Active Biotech currently holds three projects in its portfolio: The wholly… January 31, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 24 Jun 2022 Study reveals progress for those with hepatitis B …treatment-related serious adverse events and two patients with mild, rapidly resolving transaminitis. Enhanced immune response VTP-300 is a novel immunotherapy, dosed in a prime-boost regimen, whereby the immune system is… June 24, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2022 Tetris Pharma launches hypoglycemia injector pen in Germany …launch of Ogluo means that patients living with diabetes in Germany who may experience severe hypoglycamia will now have a new option to tackle those events. We look forward to… November 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Oct 2017 German Drug to Stop the Progression of Alzheimer’s Enters Phase IIb Probiodrug is ready to start a Phase IIb trial with an Alzheimer’s drug that prevents the formation of Aβ plaques before the disease progresses. The German biotech Probiodrug is getting… October 16, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jan 2023 Beyond Biotech podcast 30: Advanced Therapies Congress, BioAlps, Bionter, C2i Genomics …by creating synergies between academia, entrepreneurs, investors, authorities and new businesses. It offers networking and support opportunities through regional, national and international events, while promoting BioAlps on the global stage…. January 20, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 23 Mar 2023 Hearing loss research: Five advancements in the past year …Patricia White, a professor of Neuroscience and Otolaryngology at the University of Rochester Medical Center. Eventually, it was found that the activation of ERBB2 triggered a cascade of cellular events… March 23, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 10 Jul 2024 Biotech’s battle against skeletal dysplasia: Ray of hope for children with rare genetic disorder …Most cases of achondroplasia occur due to a sudden mutation in the FGFR3 gene, which is short for fibroblast growth factor receptor. This prevents bone growth and can lead to… July 10, 2024 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2019 Cellestia Secures €18M to Develop First-in-Class Cancer Drug Basel-based Cellestia Biotech has closed a €18M Series B financing round to help progress its first-in-class, targeted cancer drug to the clinic. The Swiss company is focusing on treating cancers… December 18, 2019 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Expert Advice 18 Apr 2023 Pharmacovigilance – how to deal with the data …from various data sources, with over 250,000 adverse events coming from U.S. citizens alone every year. Safety teams need a more efficient way of managing safety caseloads and effectively using… April 18, 2023 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 25 Sep 2017 Sanofi ‘Super-Antibody’ HIV Treatment Kills the Majority of Virus Strains …remains high. To tackle this, a lot of innovative research across Europe is underway to find an effective therapy. For example, Abivax’s HIV treatment completely removes the virus and prevents… September 25, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jun 2023 New way of identifying proteins supports drug development …In the researchers’ experiments with this new scanning method, a completely new function of the protein survivin was also discovered. This protein is mainly prominent in embryo cells and prevents… June 15, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2023 Bladder cancer investigational therapy may be given at home …(five doses and four doses, respectively) due to adverse events (AEs) unrelated to treatment. All eight patients were evaluable for treatment response, and 6 of 8 (75%) achieved a complete… February 16, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email